ERBB2 and neoplasm: However, increasing numbers of experimental and clinical studies indicate that following treatment with HER2-targeted therapies tumors can activate a variety of mechanisms to resist antibody binding and eject the cytotoxic payload of ADCs, leading to tumor cell persistence.